Article

Liposomes with entrapped doxorubicin exhibit extended blood residence times.

Canadian Liposome Co. Ltd, North Vancouver, Canada.
Biochimica et Biophysica Acta (Impact Factor: 4.66). 04/1990; 1023(1):133-9. DOI: 10.1016/0005-2736(90)90018-J
Source: PubMed

ABSTRACT The blood residence time of liposomes with entrapped doxorubicin is shown to be significantly longer than for identically prepared empty liposomes. Liposomal doxorubicin systems with a drug-to-lipid ratio of 0.2 (w/w) were administered at a dose of 100 mg lipid/kg. Both doxorubicin and liposomal lipid were quantified in order to assess in vivo stability and blood residence times. For empty vesicles composed of phosphatidylcholine (PC)/cholesterol (55:45, mole ratio) and sized through filters of 100 nm pore size, 15-25% of the administered lipid dose was recovered in the blood 24 h after i.v. injection. The percentage of the dose retained in the circulation at 24 h increased 2-3-fold when the liposomes contain entrapped doxorubicin. For 100 nm distearoyl PC/chol liposomal doxorubicin systems, as much as 80% of the injected dose of lipid and drug remain within the blood compartment 24 h after i.v. administration.

0 Bookmarks
 · 
70 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The internalization of bioactive molecules is one of the most critical problems to overcome in theranostics. In order to improve pharmacokinetic and pharmacodynamic properties, synthetic transporters are widely investigated. A new nanotechnological transporter, gH625, is based on a viral peptide sequence derived from the herpes simplex virus type 1 glycoprotein H (gH) that has proved to be a useful delivery vehicle, due to its intrinsic properties of inducing membrane perturbation. The peptide functionalization with several kinds of nanoparticles like quantum dots, dendrimers, and liposomes could be of particular interest in biomedical applications to improve drug release within cells, to increase site-specific action, and eventually to reduce related cytotoxicity.
    Journal of Nanophotonics 01/2013; · 1.45 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Complex formation between polymers and organic molecules is an interesting topic in polymer physics. Compared to the influence of small molecules on polymer assembly, there are fewer examples demonstrating the effect of polymers on the supramolecular structures formed by organic molecules. In this paper, we first prove that doxorubicin (DOX), a common anti-tumour drug, assembles into fibril-like aggregates in phosphate buffer (pH 7.4) and then show that the assembly of DOX was influenced by the complexation with an amphiphilic poly (amino acid) derivative, i.e. cholate-grafted poly-L-lysine (PLL-CA). With PLL-CA, the DOX fibrils converted to helix structured nano-spindles, whilst the presence of PLL led to minor change on the morphology of PLL/DOX complex compared to the DOX aggregates, which is attributed to the amplitude of intermolecular interactions. As a DNA intercalating agent, the aggregation of DOX on its biofunctionality was also investigated, showing that the formation of fibril assemblies was unfavourable for the cellular internalization of DOX and caused lower cytotoxicity to DOX resistance MCF-7 cells, whereas the polymer/DOX complexes gained an improved cell uptake on the MCF-7/ADR cell line due to an enhanced electrostatic interaction between the complexes and the cell membrane.
    Polym. Chem. 07/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: We conducted a phase III multicenter randomized trial to compare the efficacy of the combination of liposome encapsulated doxorubicin (Myocet©) plus either cyclophosphamide (MC) or vinorelbine (MV). Since July 2006, 233 patients affected with metastatic breast cancer were randomized to receive the combination of Myocet (M) 60 mg/m2 i.v. plus cyclophosphamide (C) 600 mg/m2 on Day 1 of a 21‑day cycle (Arm A) or Myocet (M) at 50 mg/m2 plus vinorelbine (V) 25 mg/m2 i.v. on Day 1 and V 60 mg/m2 orally on Day 8 on a 21‑day cycle (Arm B). The primary endpoints of the study was time to progression (TTP); secondary endpoints were RR, toxicity and OS. Response was observed in 53/116 (45.7%) evaluable patients of Arm A vs. 51/112 (45.5%) of Arm B, respectively (P=NS). Median TTP was 41 weeks (95% CI, 32‑51) and 34 weeks (95% CI, 26‑39), for M/C and M/V, respectively (P=0.0234). The difference in median OS was not statistically significant (131 vs. 122 weeks; P=0.107). With regard to toxicity, patients treated with MV showed a slight increase of neutropenia and constipation, as compared to those treated with MC. No clinical signs of cardiotoxicity were observed. The MC combination remains as an unbeaten 'standard' in first line treatment of MBC.
    International Journal of Oncology 08/2014; · 2.77 Impact Factor

Preview

Download
0 Downloads
Available from